MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 (MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5).
Administration of electrolytes to correct deficiencies or maintain homeostasis; no pharmacological target.
| Metabolism | Electrolytes are not metabolized; excreted primarily by kidneys. |
| Excretion | Electrolytes are primarily eliminated via renal excretion ( >95% ). Biliary/fecal elimination is negligible (<5%). |
| Half-life | The half-life is not applicable as a single value because electrolytes are homeostatically regulated. For potassium, the terminal elimination half-life is approximately 12 hours in healthy individuals, but it is highly dependent on renal function and serum levels. |
| Protein binding | Electrolytes are minimally protein-bound: Sodium <5%, Potassium <5%, Calcium ~40-50% (bound to albumin), Magnesium ~30% (bound to albumin), Chloride <5%, Bicarbonate <5%. |
| Volume of Distribution | Sodium: 0.6-0.7 L/kg (primarily extracellular); Potassium: 4-5 L/kg (mainly intracellular); Calcium: 0.3-0.5 L/kg; Magnesium: 0.5-0.7 L/kg. Reflects distribution into body fluid compartments. |
| Bioavailability | Intravenous: 100%. Not administered via other routes; oral supplementation is available separately. |
| Onset of Action | Intravenous administration: Immediate (within seconds to minutes) as electrolytes directly enter the bloodstream. |
| Duration of Action | Duration depends on the specific electrolyte and patient's homeostasis. For example, potassium replacement effects last hours to days; continuous infusion is often needed to maintain levels. Clinical monitoring required. |
Intravenous administration of 500-1000 mL at a rate of up to 1 L/hour, adjusted based on electrolyte status and fluid balance.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in anuria or severe renal impairment (GFR <30 mL/min) due to risk of electrolyte overload. For GFR 30-60 mL/min, reduce infusion rate and monitor electrolytes closely. |
| Liver impairment | No specific Child-Pugh based dose adjustments; however, monitor for electrolyte disturbances, particularly in severe hepatic impairment (Child-Pugh C) due to altered metabolism. |
| Pediatric use | Intravenous dosing based on weight: 20-30 mL/kg/day, adjusted according to serum electrolyte levels and clinical condition. Infuse at a rate not exceeding 5 mL/kg/hour. |
| Geriatric use | Use with caution due to age-related decline in renal function; start with lower infusion rates (e.g., 250-500 mL over 2-4 hours) and monitor renal function and electrolytes frequently. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 (MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5).
| Breastfeeding | Generally safe; electrolytes are naturally present in breast milk and transfer into milk in proportion to maternal plasma levels. M/P ratio not established but considered 1:1. No adverse effects expected in breastfed infants. |
| Teratogenic Risk | No teratogenic risk; electrolytes are physiologic substances and essential for normal fetal development. No increased risk of congenital anomalies at therapeutic doses. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hyperkalemia, hypercalcemia, hypernatremia, or hypermagnesemia","Severe renal impairment with oliguria/anuria","Addison's disease (unrelated to sodium source)","Concurrent use of potassium-sparing diuretics (if contains potassium)"]
| Precautions | ["Monitor serum electrolytes, fluid balance, and acid-base status","Use with caution in patients with renal impairment, heart failure, or conditions predisposing to fluid/electrolyte disturbances","Risk of hyperkalemia with potassium-containing solutions","Risk of hypercalcemia if calcium is present"] |
Loading safety data…
| Monitor maternal serum electrolyte levels, acid-base balance, renal function, and fluid status. Fetal heart rate monitoring if maternal electrolyte disturbances occur. No specific fetal surveillance required for normal use. |
| Fertility Effects | No known adverse effects on fertility; electrolytes are essential for normal reproductive function. Therapeutic doses do not impair fertility. |